^
Association details:
| Biomarker: | CLU-NRG1 fusion |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Bizengri (zenocutuzumab-zbco) (HER2 inhibitor, HER3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The HER2×HER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions
Published date:
03/10/2021
Excerpt:
…a high grade serous ovarian cancer harboring a CLU-NRG1 fusion (OV-10-0050)...Treatment of mice bearing LUAD-0061AS3, ST3204 and OV-10-0050 PDX tumors (2.5, 8, 25 mg/kg, QW) caused a dose-dependent inhibition of tumor growth, with tumor shrinkage observed at higher doses.
